Know Cancer

forgot password

Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer

21 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer

Inclusion Criteria:

- Prostate cancer diagnosis prior to treatment

- Age 21 years or older

- Signed informed subject consent

- Prostatectomy as planned prostate cancer treatment

Exclusion Criteria:

- Men who do not choose prostatectomy

- Men who have undergone any neoadjuvant therapy

- Men who have cardiac pacemakers or other implanted electronic devices

- Men who have any surgically implanted metal

- Men who have had any surgical procedure that precludes placement of endorectal probe

- Indication of dementia or memory issues listed on problem list

Type of Study:


Study Design:

Observational Model: Case-Crossover, Time Perspective: Prospective

Outcome Measure:

Number of participants with increased intraprostatic lipid concentration

Outcome Description:

Determine the correlation between the amount of intraprostatic lipid using 1H magnetic resonance spectroscopic imaging (MRSI) with an endorectal coil obtained prior to prostatectomy with fatty acid synthase protein expression measured in benign and cancer tissue from prostatectomy samples.

Outcome Time Frame:

Up to 3 years

Safety Issue:


Principal Investigator

Jackilen Shannon, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Oregon Health and Science University


United States: Institutional Review Board

Study ID:

PC110361/ PC110361P1



Start Date:

January 2013

Completion Date:

March 2015

Related Keywords:

  • Prostate Cancer
  • prostate cancer aggressiveness
  • magnetic resonance imaging
  • fatty acid synthase
  • Prostatic Neoplasms



Portland VA Medical CenterPortland, Oregon  97239
Oregon Health & Science University Advanced Imaging Research CenterPortland, Oregon  97239